| 3.85 -0.28 (-6.78%) | 07-10 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 4.74 |
1-year : | 5.24 |
| Resists | First : | 4.06 |
Second : | 4.48 |
| Pivot price | 3.92  |
|||
| Supports | First : | 3.38 |
Second : | 2.81 |
| MAs | MA(5) : | 4.01 |
MA(20) : | 3.82 |
| MA(100) : | 3.36 |
MA(250) : | 2.84 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 54.3 |
D(3) : | 57.9 |
| RSI | RSI(14): 50.5 |
|||
| 52-week | High : | 4.59 | Low : | 1.35 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ ELDN ] has closed above bottom band by 35.9%. Bollinger Bands are 28.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 4.12 - 4.15 | 4.15 - 4.17 |
| Low: | 3.75 - 3.78 | 3.78 - 3.8 |
| Close: | 3.81 - 3.85 | 3.85 - 3.89 |
Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating innovative treatments for individuals battling autoimmune disorders, amyotrophic lateral sclerosis (ALS), and those undergoing organ or cell transplantation. Their flagship therapeutic candidate, AT-1501, is a humanized monoclonal antibody engineered to specifically target CD40 Ligand, a crucial protein found on the surface of immune system T cells. This compound is currently undergoing Phase 2a clinical studies for ALS treatment and Phase 2 trials for islet cell transplantation, aiming to address type 1 diabetes. Previously known as Novus Therapeutics, Inc., the company adopted its current name, Eledon Pharmaceuticals, Inc., in January 2021. Its corporate headquarters are located in Irvine, California.
Wed, 08 Jul 2026
The Longevity Protein Race Reaches Manufacturing: One Microcap Just Completed A GMP Master Cell Bank For Its Anti-Aging Klotho Therapy - Sahm
Mon, 29 Jun 2026
Eledon Pharmaceuticals, Inc.(NasdaqCM:ELDN) dropped from Russell 3000 Value Benchmark - marketscreener.com
Thu, 25 Jun 2026
ELDN Forecast — Price Target — Prediction for 2027 - TradingView
Mon, 22 Jun 2026
Eledon (NASDAQ: ELDN) holders approve share increase and board slate - Stock Titan
Thu, 18 Jun 2026
Eledon Pharma To Present At The American Transplant Congress - RTTNews
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 77 (M) |
| Shares Float | 70 (M) |
| Held by Insiders | 1 (%) |
| Held by Institutions | 59.2 (%) |
| Shares Short | 7,500 (K) |
| Shares Short P.Month | 6,780 (K) |
| EPS | -0.77 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.32 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -35.1 % |
| Return on Equity (ttm) | -72.7 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -69 (M) |
| Levered Free Cash Flow | -40 (M) |
| PE Ratio | -5 |
| PEG Ratio | 0 |
| Price to Book value | 2.91 |
| Price to Sales | 0 |
| Price to Cash Flow | -4.32 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|